About the Event
InflammX is in the process of finalizing financing to move their program for Xiflam into clinical trials. But, there is still an opportunity for those interested in co-investing.
In proof-of-concept testing, InflammX has demonstrated Xiflam’s ability to restore normal biology to the dysregulated inflammasomes which are involved in Dry Age-Related Macular Degeneration and Diabetic Retinopathy. Orally administered Xiflam is supported by a safety database of more than 1000 points showing the drug to be well tolerated with no safety concerns.
Join our webinar to hear directly from InflammX CEO, Dr. Brian Levy as he talks about the opportunity to co-invest in the company and help improve the vision of people with Dry AMD and Diabetic Retinopathy.